Blood disorders ppt 1. The established cell-based, high-throughput screening approach provides a powerful tool for identifying new vitamin K antagonists that function as anticoagulants.
The other 3 drugs mainly affect vitamin K availability within the cells. 2. Topics under Bleeding Disorder.
Coagulopathy from drugs that inhibit the reduction of vitamin K epoxide, but not vitamin K, can be rescued by administering vitamin K. Don't already have an account? The molecular mechanisms underlying the inactivation of VKOR and VKR by these drugs are clarified. Old drug, new purpose?Vitamin K epoxide reductase contributes to protein disulfide formation and redox homeostasis within the endoplasmic reticulumDisulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum: a protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reductionMode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosisReduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen speciesNQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levelsNAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reactionVitamin K1 hydroquinone formation catalyzed by DT-diaphoraseThe potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidationKinetic study of free-radical-scavenging action of biological hydroquinones (reduced forms of ubiquinone, vitamin K and tocopherol quinone) in solutionWarfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modelingThe clinical pharmacokinetics of itraconazole: an overviewDrug interactions involving warfarin: practice tool and practical management tipsSignalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazolePossible antiretroviral therapy-warfarin drug interaction
A cell-based screening of 727 drugs in the NIH Clinical Collection library identified 9 drugs that may cause bleeding disorders. Causes of Blood conditions (Diseases Database): The follow list shows some of the possible medical causes of Blood conditions that are listed by the Diseases Database: . Search for other works by this author on:
Xuejie Chen, Caihong Li, Da-Yun Jin, Brian Ingram, Zhenyu Hao, Xue Bai, Darrel W. Stafford, Keping Hu, Jian-Ke Tie; A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle. A systematic reviewPotential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal TractUse of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysisAssociation of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial HemorrhageBleeding in patients with infections: are antibiotics helping or hurting?Lactic Acidosis Induced by Linezolid Mimics Symptoms of an Acute Intracranial Bleed: A Case Report and Literature ReviewA Case of Alveolar Bleeding from Clotting Abnormality by CefmetazoleClofazimine Enteropathy: A Rare and Underrecognized Complication of Mycobacterial TherapyIatrogenic metrorrhagia after the use of itraconazole for onychomycosisAre drug-related dental management cautions in Lexicomp Online for Dentistry evidence-based? To research the causes of Blood conditions, consider researching the causes of these these diseases that may be … A systematic review of the literatureGingival bleeding, a possible “serious” adverse drug reaction: an observational study in the French PharmacoVigilance DatabaseFatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case ReportSodium dehydroacetate induces coagulation dysfunction by inhibiting liver vitamin K epoxide reductase complex subunit 1 in Wistar ratsFunctional Study of the Vitamin K Cycle Enzymes in Live CellsFunctional study of the vitamin K cycle in mammalian cellsEvaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cellsCharacterization of vitamin K-dependent carboxylase mutations that cause bleeding and nonbleeding disordersEvaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieuThe conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteinesParacetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycleIdentification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzymeThe vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylationSex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patternsGender and inter-species influence on coagulation tests of rats and miceEvidence that warfarin anticoagulant action involves two distinct reductase activitiesEffects of orlistat on fat-soluble vitamins in obese adolescentsIdentification and purification of vitamin K-dependent proteins and peptides with monoclonal antibodies specific for gamma -carboxyglutamyl (Gla) residuesVitamin K1 and therapy of massive warfarin overdoseVitamin K1 disposition and therapy of warfarin overdoseVitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysisVitamin K1 reduction in human liver: location of the coumarin-drug-insensitive enzymeDapsone hypersensitivity syndrome in an adolescent during treatment during of leprosyDiffuse alveolar hemorrhage following itraconazole injectionWarfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibitionWarfarin traps human vitamin K epoxide reductase in an intermediate state during electron transferWarfarin and vitamin K compete for binding to Phe55 in human VKORWarfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomesModel studies for a molecular mechanism of action of oral anticoagulantsInhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of ureasePossible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749Lansoprazole inhibits the cysteine protease legumain by binding to the active siteEngineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the systemResearch perspective: potential role of nitazoxanide in ovarian cancer treatment.